Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies
Business Wire•21/10/2026•08:00 ET
0
Key Highlights
- ➤EB-003 completed over 70 IND-enabling in vitro ADMET assays
- ➤EB-003 showed favorable predicted intestinal absorption in human cell-based tests
- ➤EB-003 demonstrated liver-enzyme stability across multiple species, including humans
- ➤EB-003 showed no significant major enzyme or transporter inhibition or induction
- ➤Enveric plans to advance EB-003 toward a first-in-human clinical trial
Expert Statements
Joseph Tucker, Director and Chief Executive Officer of Enveric Biosciences
“These results represent an important milestone in the development of EB-003, provide additional support for its preclinical development profile, and support its continued advancement toward a planned first-in-human clinical trial.”
Joseph Tucker, Director and Chief Executive Officer of Enveric Biosciences
“So far, the data generated from our IND enabling studies have showcased a differentiated pharmacological profile for EB-003, with the potential to preserve certain therapeutic benefits associated with neuroplasticity while minimizing safety concerns and hallucinogenic impacts.”
Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies
Completed IND-enabling in vitro Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) studies, demonstrating favorable and efficient oral absorption and systemic bioavailability
Get started
Create a free account to read the full story.